Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Blue, Yellow Letters to Cover Regenerative Medicines
November 11, 2014
- MHLW Mulls Creating Rules under Law for Patient-Initiated Mixed-Care System
November 11, 2014
- PAFSC First Committee to Discuss Takeda’s Vonoprazan on Nov. 21
November 11, 2014
- US FDA Withdraws Tentative Approvals for 2 Generic Drugs of Ranbaxy
November 11, 2014
- 5 Experts Likely to Review Regenerative Medicines for Expedited Senshin-Iryo Scheme
November 10, 2014
- Health Ministry Panel Includes Legal Regulations for Clinical Research in Draft Outline
November 10, 2014
- Chuikyo OKs Patient-Initiated Mixed-Care System, Use of Investigational Drugs for Non-Enrollable Patients
November 7, 2014
- Chuikyo Approves Insurance Coverage for Regenerative Medicine Products upon Conditional Approval
November 7, 2014
- PMDA Assessing Reminyl for Risk of Acute Generalized Exanthematous Pustulosis
November 6, 2014
- MHLW Issues Notifications on Drug/Medical Device Combination Products
November 6, 2014
- Sept. Drug Price Settlement Rate at 92.6% as Big Hospitals, Pharmacies Take Quantum Leap
November 6, 2014
- Editor’s Pick: Five Healthcare News Headlines for October 20 - October 31
November 5, 2014
- PMDA Establishes Office of Generic Drugs to Expedite Review and Consultation for Generic Drugs
November 4, 2014
- Cabinet OKs Appointment of Keio Prof as Japan NIH Head
October 31, 2014
- MHLW to Issue Notification with Survey Form on Adverse Reactions to HPV Vaccines
October 31, 2014
- Lantus Biosimilars Likely to Be OKed by Year-End: First Committee
October 30, 2014
- Welfare Recipients Should Pay Difference between Generic and Branded Drug Prices: MOF
October 29, 2014
- Health Ministry Shares Views on PI Studies for Japanese Patients
October 29, 2014
- Risk of Fulminant Hepatitis Added to Lyrica Package Insert: MHLW
October 29, 2014
- PAFSC Second Committee Backs Approval of Janssen’s Combination Tablet for HIV
October 28, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…